Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
I notice that the trinity note contains the following regarding the SCIB1 trial:
'The study could complete enrolment by mid- to late-2022, with clinical data following some months later.'
This implies that further patient shave been recruited - if we were still stuck at one patient then there is no way that recruitment would be expected to complete this year. Interesting that they go so far as indicating that recruitment could be done by mid 2022 - must being seeing some good momentum in recruitment for this to be a possibility.
I do recall Lindy saying that Professor Christian Ottensmeier had patients lined up for as soon as the trial started so assuming that these patients have not succumbed in the meantime the first patient dosed notification may come within days.
Hi Cleanerworld - if you go on the other site (starts with A then D then V the F then N) you are able to message other posters using the message facility. You can sign up for free. You are welcome to message me on that site if you wish (I have the same user name as on this site).
rigga - presumably they are getting on with the things which will ultimately significantly increase the value of the company. What do you expect them to be doing ? They can't control the market (many biotechs have suffered similar falls over the last few weeks).
Vortex is a good product but costs multiples of the cost of Parsortix for a start.
Vortex hasn't the journey to FDA approval i.e. years behind AGL.
Parsortix has been the subject of far more papers and is used far more widely.
Vortex has limited funding compared to AGL so its long term future must be uncertain.
Darren, two highly respected brokers (Berenberg and Jeffries) have recently released reports on AGL. Berenberg stated that FDA approval is expected within weeks and Jeffries said that FDA approval is expected in 1Q (i.e by end March). Both Berenberg and Jeffries will have spoken to AGL in producing their reports so AGL (who are in contact with the FDA) must have given them this steer regarding the FDA timetable. This pretty much means that the FDA response could come anytime in the next few weeks.
The fact that they have brought RG into the role now rather than wait until they find the permanent appointee strongly implies that serious deal discussions, requiring full time attention, are underway. Why bring RG in if this is not the case ? It would also explain why Diggle has not wiggled recently despite the falling SP.
Only 11 of those 39 are actually for Angle. If you want a full list of the 25 jobs that Angle are hiring for it is better to look here:-
https://angleplc.com/careers/